Short Summary
Headwater Research LLC seeks Director review of an IPR decision that found all claims of its 2013 MMS messaging patent unpatentable. The patent owner contends the Board improperly relied on expert testimony because the cited prior art (TS-23.140) does not disclose the required agent communication bus. The request asks the Director to vacate the decision and terminate the IPR.
Detailed Summary
In a Request for Director Review, Headwater Research LLC challenges the Patent Trial and Appeal Board’s Final Written Decision that declared all claims of U.S. Patent No. 8,406,733 unpatentable. The patent owner argues that the Board violated statutory requirements under 35 U.S.C. §311(b) by allowing the petitioners—Samsung Electronics, Google, and Samsung Electronics America—to rely on expert testimony to fill gaps where the sole prior‑art reference, TS-23.140, fails to disclose the “agent communication bus” limitation required by the claims. Citing Board regulations and Federal Circuit precedent, Headwater requests that the Director vacate the decision and terminate the IPR, or alternatively find the challenged claims unpatentable. The filing underscores the importance of strict adherence to prior‑art‑only grounds in inter‑partes reviews.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co., Ltd. et al. vs Headwater Research LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Dolby Laboratories, Inc. et al.vsInterDigital Madison Patent Holdings, SAS et al.
Dolby Laboratories has filed an IPR petition challenging U.S. Patent 9,185,268, which covers methods for color correcting display content. The petition asserts that the claims are obvious over a combination of prior‑art references and requests the Board to institute the review.
Nexus Pharmaceuticals LLCvsExela Pharma Sciences, LLC
Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.
Activision Blizzard, Inc.vsMilestone Entertainment, LLC
Milestone Entertainment’s sur‑reply argues that Activision Blizzard’s IPR petition fails on both the Walker prior‑art and Kelly obviousness grounds, citing lack of written‑description support and missing disclosures for key claim limitations.
Ajinomoto Co., Inc.vsAbTis Co., Ltd.
Ajinomoto has filed an IPR petition challenging AbTis’s U.S. Patent 11,896,675 covering site‑specific antibody‑drug conjugates. The petitioner alleges lack of written description, improper priority, and that all 13 claims are anticipated or obvious over several pre‑grant publications and conference disclosures. The petition seeks cancellation of every claim.
Intas Pharmaceuticals, Ltd. et al.vsAtossa Therapeutics, Inc.
The Director denied Intas Pharmaceuticals' request for review of the institution decision in IPR2025-00799, leaving Atossa Therapeutics' Patent 11,261,151 in place.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.